← back to search

Luca Piccoli

University of Verona · IT
Area of research
Infectious Diseases · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, Monoclonal and Polyclonal Antibodies Research, COVID-19 Clinical Research Studies, and Viral gastroenteritis research and epidemiology.
h-index
40
citations
12,188
works
99
NIH funding
primary concept
Medicine
email

Recent publications

Neutralization, effector function and immune imprinting of Omicron variants
Nature 2023cited by 178position: middledoi
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Science 2022cited by 255position: middledoi
Antibodies to a Citrullinated Porphyromonas gingivalis Epitope Are Increased in Early Rheumatoid Arthritis, and Can Be Produced by Gingival Tissue B Cells: Implications for a Bacterial Origin in RA Etiology
Frontiers in Immunology 2022cited by 39position: middledoi
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Nature 2021cited by 1,200position: middledoi
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
Cell 2021cited by 655position: middledoi
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Nature 2021cited by 582position: middledoi
Broad betacoronavirus neutralization by a stem helix–specific human antibody
Science 2021cited by 429position: middledoi
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Nature 2021cited by 213position: middledoi
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
Cell 2020cited by 1,623position: firstdoi
Different Hierarchies of Anti–Modified Protein Autoantibody Reactivities in Rheumatoid Arthritis
Arthritis & Rheumatology 2020cited by 80position: middledoi
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study
Journal of Neuroimmunology 2018cited by 25position: middledoi
Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
Multiple Sclerosis Journal 2017cited by 103position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Nicky Dunn · Karolinska Institutet1 papers (2017–2017)Ragnhild Stålesen · Karolinska University Hospital1 papers (2020–2020)Fredrik Piehl · Karolinska University Hospital1 papers (2017–2017)Ali Manouchehrinia · Alberta Health Services1 papers (2017–2017)Vivianne Malmström · Karolinska Institutet1 papers (2020–2020)Monika Hansson · Karolinska University Hospital1 papers (2020–2020)Philip J. Titcombe · University of Minnesota Medical Center1 papers (2020–2020)Johanna Stéen · Karolinska University Hospital1 papers (2020–2020)Katharina Fink · Karolinska University Hospital1 papers (2017–2017)Lena Israelsson · Karolinska University Hospital1 papers (2020–2020)Malin Ryner · Karolinska Institutet1 papers (2017–2017)Khaled Amara · Karolinska University Hospital1 papers (2020–2020)Karl Skriner · Freie Universität Berlin1 papers (2020–2020)Anna Fogdell‐Hahn · Affibody (Sweden)1 papers (2017–2017)Björn Forstström · Science for Life Laboratory1 papers (2020–2020)Anca I. Catrina · Karolinska University Hospital1 papers (2020–2020)Peter Ström · University of Pittsburgh1 papers (2020–2020)Alexander Juto · Karolinska University Hospital1 papers (2017–2017)Karin Lundberg · Karolinska University Hospital1 papers (2020–2020)Caroline Grönwall · Karolinska Institutet1 papers (2020–2020)